# Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

> **NCT00458913** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 82 (actual)

## Conditions studied

- Malignant Mesothelioma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00458913
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2010-04
- **Final completion:** 2012-03
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2018-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458913, "Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00458913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*